Pfizer Lifts 2025 Profit Forecast, Surpasses Q3 Earnings Expectations

Pfizer has raised its full-year profit forecast for the second quarter in a row. The company now expects to earn $3.00 to $3.15 per share for 2025. This is an increase from its earlier prediction of $2.90 to $3.10. Strong demand for key treatments drove this positive outlook.

The drugmaker reported excellent third-quarter earnings. Adjusted earnings hit 87 cents a share. This comfortably beat analysts’ expectations of 63 cents per share. Sales of its successful heart treatment and blood thinner drove the jump. However, sales of the COVID antiviral Paxlovid saw a 55% drop.

The improved forecast comes from several factors. Pfizer is benefiting from its massive cost-cutting plan. The company expects to save billions by 2027. It also sees a favorable impact from foreign exchange rates.

Pfizer currently faces a legal fight with Novo Nordisk. The battle is over acquiring obesity-drug developer Metsera. Shares of Pfizer rose slightly following the upbeat results. The company continues to focus on strengthening its product portfolio and pipeline for the future.